Danish Pharmacovigilance Update, November 2016

09 December 2016

In this issue:

  • Suicidal behaviour and suicidal ideation have been reported as suspected adverse reactions to the dermatologic medicinal product Otezla® (apremilast)
  • Focus on reported adverse reactions to selected biological medicines
  • Most recent Direct Healthcare Professional Communications (DHPCs)
  • EU's list of recommendations on safety signals
  • Danish Pharmacovigilance Update celebrates 7-year anniversary


Danish Pharmacovigilance Update, November 2016

Did you get answers to your questions?

Please tell us how we can improve our website? Please note that we do not answer questions asked via this feature.